Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

A novel PPAR{gamma} agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways

Journal Article · · Biochemical and Biophysical Research Communications
 [1]; ; ;  [2]; ;  [1];  [1];  [3];  [4];  [5];  [4];  [1];  [1]
  1. Skeletal Diseases Genome Research Center, Kyungpook National University Hospital, Daegu (Korea, Republic of)
  2. Center for Metabolic Syndrome Therapeutics, Korea Research Institute of Chemical Technology, Daejeon (Korea, Republic of)
  3. Department of Pharmacology, School of Medicine, Kyungpook National University, Daegu (Korea, Republic of)
  4. Department of Oral Pathology, IHBR, School of Dentistry, Kyungpook National University, Daegu (Korea, Republic of)
  5. Department of Orthopaedic Surgery, School of Medicine, Catholic University of Daegu, Daegu (Korea, Republic of)

We investigated the effects of a novel peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) agonist, KR62776, on osteoclast differentiation and function, and on the underlying signaling pathways. KR62776 markedly suppressed differentiation into osteoclasts in various osteoclast model systems, including bone marrow mononuclear (BMM) cells and a co-culture of calvarial osteoblasts and BMM cells. KR62776 suppressed the activation of tartrate-resistant acid phosphatase (TRAP) and the expression of genes associated with osteoclast differentiation, such as TRAP, dendritic cell-specific transmembrane protein (DC-STAMP), and osteoclast-associated receptor (OSCAR). Furthermore, KR62776 reduced resorption pit formation in osteoclasts, and down-regulated genes essential for osteoclast activity, such as Src and {alpha}v{beta}3 integrin. An analysis of a signaling pathway showed that KR62776 inhibited the receptor activator of nuclear factor-{kappa}B ligand (RANKL)-induced activation of p38 mitogen-activated protein kinase (p38MAPK), extracellular regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and nuclear factor-{kappa}B (NF-{kappa}B). Together, these results demonstrate that KR62776 negatively affects osteoclast differentiation and activity by inhibiting the RANKL-induced activation of MAP kinases and NF-{kappa}B.

OSTI ID:
21255842
Journal Information:
Biochemical and Biophysical Research Communications, Journal Name: Biochemical and Biophysical Research Communications Journal Issue: 3 Vol. 378; ISSN 0006-291X; ISSN BBRCA9
Country of Publication:
United States
Language:
English

Similar Records

Ly49Q, an ITIM-bearing NK receptor, positively regulates osteoclast differentiation
Journal Article · Thu Mar 11 23:00:00 EST 2010 · Biochemical and Biophysical Research Communications · OSTI ID:22202405

Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB
Journal Article · Thu Feb 14 23:00:00 EST 2013 · Experimental Cell Research · OSTI ID:22278211

Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways
Journal Article · Fri Jul 04 00:00:00 EDT 2014 · Biochemical and Biophysical Research Communications · OSTI ID:22416605